From what I gather so far on the internet cd49d + makes it more difficult for ibrutinib to do its job and suggests shoter overall survival. Do you find this to be a useful marker? Does it imply anything else? Trying to tease bits of info out of dense articles.
Written by
DriedSeaweed
To view profiles and participate in discussions please or .
which is similar. I had flow cytometry done in May and they didn't probe for CD49b. I guess I'm going to try to look into this. This must have come out from studies of people who did not respond well to IB, so its all fairly new.
From what I have read so far it is linked more to SLL and it is not commonly looked for in usa. An NIH test referenced it. My flow cytometry test from private practice doctor does not look for it.
CD49d expression has only recently been tested for and is associated with a poorer response to Ibrutinib. NOTCH1 is strongly correlated with Richter’s transformation and trisomy 12 is associated with both NOTCH1 and CD49d.
It would seem to be reasonable to test for CD49d prior to Ibrutinib treatment.
They have that drug already, Zydelig (idelalisib). There are few trials looking at Imbruvica (ibrutinib) and Zydelig (idelalisib) used in combination...
Yes... perhaps next gen duvelisib then... I had absolutely no problems on Zydelig (idelalisib)/rituxan, wish I could still be on it... 😀👍🏼 It simply requires prophylactics and CMV monitoring...
Deaths were first line when used with bendamustine... terrible mistake. It can't be used first line now at all...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.